Summary
PROJECT SUMMARY The development of narrow-spectrum antibiotics against the Lyme disease-causing bacterium, Borrelia burgdorferi has the potential to significantly alter current approaches to the treatment and prevention of Lyme disease. Narrow-spectrum agents that affect only the target bacteria avoid issues of propagation of resistance in off-target bacteria, alterations in microbiome, and overgrowth of pathogenic bacteria. However, physical screening of compounds for activity against multiple bacteria such as through traditional high-throughput screens is highly inefficient due to its very l
